Trial ID or NCT#
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma
Contact us to find out if this trial is right for you.
Jee Min Lee